

LSU Health Science Center

LSU Health Digital Scholar

Medical Research Day

2022 Medical Research Day Posters

Oct 13th, 12:00 AM

Genitourinary and Sexual Health Care for Women with Cancer: Overlooked Quality of Life Indicators

Hannah C. DellaCroce

LSU Health Sciences Center- New Orleans

Nancy L. Ren

LSU Health Sciences Center- New Orleans, nren@lsuhsc.edu

Andrew G. Chapple

LSU Health Sciences Center- New Orleans, achapp@lsuhsc.edu

Sydni Barras

LSU Health Sciences Center- New Orleans, sbarra@lsuhsc.edu

Shawna Morron

LSU Health Sciences Center- New Orleans

See next page for additional authors

Follow this and additional works at: <https://digitalscholar.lsuhscc.edu/sommrd>



Part of the [Obstetrics and Gynecology Commons](#)

Recommended Citation

DellaCroce, Hannah C.; Ren, Nancy L.; Chapple, Andrew G.; Barras, Sydni; Morron, Shawna; Castellano, Tara; Nair, Navya; and Jernigan, Amelia, "Genitourinary and Sexual Health Care for Women with Cancer: Overlooked Quality of Life Indicators" (2022). *Medical Research Day*. 22.

<https://digitalscholar.lsuhscc.edu/sommrd/2022MRD/Posters/22>

This Event is brought to you for free and open access by the School of Medicine at LSU Health Digital Scholar. It has been accepted for inclusion in Medical Research Day by an authorized administrator of LSU Health Digital Scholar. For more information, please contact aolini@lsuhsc.edu.

Presenter Information

Hannah C. DellaCroce, Nancy L. Ren, Andrew G. Chapple, Sydni Barras, Shawna Morron, Tara Castellano, Navya Nair, and Amelia Jernigan

Hannah C. DellaCroce¹, Nancy L. Ren¹, Andrew G. Chapple, PhD², Sydni Barras¹, Shawna Morron, PA-C³, Tara Castellano, MD⁴, Navya Nair, MD, MPH, FACOG, FACS⁴, Amelia Jernigan, MD⁴

¹Louisiana State University Health Sciences Center New Orleans School of Medicine, ²Louisiana State University Health Sciences Center New Orleans Department of Public Health, ³Louisiana State University Health Sciences Center New Orleans School of Allied Health, ⁴Louisiana State University Health Sciences Center New Orleans Department of Obstetrics and Gynecology, Division of Gynecologic Oncology

Introduction

Genitourinary health and sexual well-being are critical aspects of quality of life and overall health, especially for patients with malignancy who face the negative physical and emotional consequences of cancer and cancer treatment. However, evidence suggests that physicians rarely address these concerns in clinical practice. As cancer survivorship continues to improve with advancements in detection and treatment, the need for supportive gynecologic and sexual health care for women with cancer is greater than ever. The purpose of this study was to characterize the prevalence of oncologist-reported counseling for genitourinary syndromes (GUS) or sexual health concerns (SHC) in women with cancer being cared for at an urban academic safety net hospital and to identify potential gaps in care for this patient population.

Methods

A retrospective study of 514 women receiving cancer treatment or follow-up cancer care from January 24, 2022, to March 31, 2022, was performed. Inclusion criteria consisted of female patients aged 18 or older with a prior or current cancer diagnosis. Demographics and clinical data were abstracted from patient charts to investigate factors associated with screening for GUS or SHC. Charts were further reviewed to determine whether the oncologist initiated a treatment or referral process for patients endorsing GUS or SHC. Statistical analyses were conducted using R statistical software version 4.0.2. Demographic variables were compared between groups using Wilcoxon rank sum tests for continuous variables and Fisher exact tests for categorical variables.

Tables and Figures





Figure 1: Model of sexual health for cancer survivors.

Source: *Seminars in Oncology Nursing*, vol. 36, Falk SJ, Dizon DS., Sexual Health Issues in Cancer Survivors.

Table 1: Genitourinary syndrome (GUS) and sexual health concern (SHC) evaluation by cancer status.

| | n (%) | GUS or SHC Counseling | | P-values |
|-----------------------|------------|-----------------------|------------|----------|
| | | Yes | No | |
| Total (n) | 514 | 68 | 446 | |
| Cancer Stage (49 N/A) | | | | .54 |
| Stage 0 | 39 (8.4) | 5 (7.8) | 34 (8.5) | |
| Stage 1 | 138 (29.7) | 22 (34.4) | 116 (28.9) | |
| Stage 2 | 108 (23.2) | 14 (21.9) | 94 (23.4) | |
| Stage 3 | 98 (21.1) | 16 (25.0) | 82 (20.4) | |
| Stage 4 | 82 (17.6) | 7 (10.9) | 75 (18.7) | |
| Cancer Type | | | | |
| Breast Cancer | 207 (40.3) | 15 (22.1) | 192 (43.0) | .001 |
| Cervical Cancer | 43 (8.4) | 16 (23.5) | 27 (6.1) | <.001 |
| Colorectal Cancer | 39 (7.6) | 2 (2.9) | 37 (8.3) | .144 |
| Ovarian Cancer | 32 (6.2) | 10 (14.7) | 22 (4.9) | .005 |
| Vulvar Cancer | 19 (3.7) | 7 (10.3) | 12 (2.7) | .007 |
| Uterine Cancer | 53 (10.3) | 16 (23.5) | 37 (8.3) | .001 |
| Other Cancer | 154 (30.0) | 7 (10.3) | 147 (33.0) | <.001 |
| Disease Status | | | | <.001 |
| Alive with Disease | 275 (53.5) | 16 (23.5) | 259 (58.1) | |
| Alive without Disease | 239 (46.5) | 52 (76.5) | 187 (41.9) | |
| Treatment Status | | | | <.001 |
| On Active Treatment | 266 (51.8) | 21 (30.9) | 245 (54.9) | |
| Not on Treatment | 248 (48.2) | 47 (69.1) | 201 (45.1) | |
| Treatment Type | | | | |
| Surgical | 371 (72.2) | 52 (76.5) | 319 (71.5) | 0.468 |
| Chemotherapy | 319 (62.1) | 39 (57.4) | 280 (62.8) | 0.422 |
| Radiation | 250 (48.6) | 32 (47.1) | 218 (48.9) | 0.796 |
| Hormonal | 127 (24.7) | 12 (17.6) | 115 (25.8) | 0.175 |
| Targeted | 168 (32.7) | 9 (13.2) | 159 (35.7) | <.001 |
| Immunotherapy | 69 (13.4) | 4 (5.9) | 65 (14.6) | 0.055 |
| Palliative | 83 (16.1) | 8 (11.8) | 75 (16.8) | 0.377 |
| No Treatment | 19 (3.7) | 1 (1.5) | 18 (4.0) | 0.492 |

Figure 2: Follow up care by symptom category.



Results

A total of 68 of 514 (13.2%) subjects were asked about GUS or SHC by their oncologist. Of the patients that had these discussions, 25 (36.8%) endorsed GUS or SHC. The majority (96.0%) of patients who reported GUS or SHC received treatment or referral for further care. Roughly one-third of gynecologic cancer survivors (37.2% of cervical cancer, 31.3% of ovarian cancer, 36.8% of vulvar cancer, and 30.2% of uterine cancer) discussed GUS or SHC with their oncologist. In contrast, only 7.2% of breast, 5.1% of colorectal, and 4.5% of other cancer survivors had documented discussions of GUS or SHC. Documented conversations about these topics were more common in patients without evidence of disease (21.8% vs. 5.8%, $p < .001$). Patients who were not on active treatment were more likely to have documented discussions than those on active treatment (19.0% vs. 7.9%, $p < .001$). Patients on targeted therapy were significantly less likely to have documented GUS or SHC conversations with their oncologist (35.7% vs. 13.2%, $p < .001$). There were no other significant differences by treatment type, race, ethnicity, need for translator, insurance status, or BMI with regards to counseling for GUS or SHC.

Conclusions

Women with gynecologic cancers were more likely to have documented GUS or SHC counseling by their oncologist than women with other cancers. Patients without evidence of disease and not receiving treatment were also more likely to have documented discussions surrounding these issues. Although only 13.2% of patients had documented GUS or SHC conversations, most of those patients were able to achieve follow-up care, illustrating a large gap in care and revealing an opportunity to address a significant quality of life issue for these patients.